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O. Sabri et al. / Alzheimer’s & Dementia- (2015) 1-112Abstract Background: Evaluation of brain b-amyloid by positron emission tomography (PET) imaging can
assist in the diagnosis of Alzheimer disease (AD) and other dementias.
Methods: Open-label, nonrandomized, multicenter, phase 3 study to validate the 18F-labeled b-am-
yloid tracer florbetaben by comparing in vivo PET imaging with post-mortem histopathology.
Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed.
Forty-six of 47 neuritic b-amyloid-positive cases were read as PET positive, and 24 of 27 neuritic b-
amyloid plaque-negative cases were read as PET negative (sensitivity 97.9% [95% confidence inter-
val or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue-scan
matched analysis was performed. In areas known to strongly accumulate b-amyloid plaques, sensi-
tivity and specificity were 82% to 90%, and 86% to 95%, respectively.
Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of
histopathology-confirmed neuritic b-amyloid plaques and may thus be a valuable adjunct to clinical
diagnosis, particularly for the exclusion of AD.
Trial registration: ClinicalTrials.gov NCT01020838.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Amyloid; PET; Florbetaben; Histopathology1. Introduction
Progress in research to improve diagnostic accuracy and
treatment for Alzheimer disease (AD) depends on the char-
acterization of underlying pathophysiologic mechanisms
[1]. With estimates of more than a decade between the onset
of b-amyloid deposition and cognitive decline in affected in-
dividuals, the opportunity exists to introduce effective
disease-modifying regimens [2]. b-Amyloid imaging may
aid this process by facilitating early diagnosis.
The International Working Group for New Research
Criteria for the Diagnosis of AD recommends consideration
of a dual clinicobiological process for diagnosis, involving
the evidence of specific cognitive impairment together with
biomarkers [3]. The recommendation was recently updated
to categorize AD biomarkers according to whether they are
involved in pathology or progression [4]. As the amyloid
cascade is considered key to the pathogenesis of AD,
b-amyloid is one such biomarker; existing techniques
involve the imaging of b-amyloid plaques in the brain or
detection of decreased b-amyloid levels in cerebrospinal
fluid [5]. The successful use of such biomarkers has the po-
tential to improve screening and diagnosis of AD. Amyloid
imaging in particular is already being used as part of the eligi-
bility criteria in large, multicenter clinical therapeutic trials.
Several 18F-labeled b-amyloid ligands have been devel-
oped for positron emission tomography (PET) [6–9].
Phase 1 and 2 trials have been performed to study the
pharmacokinetics, safety, and diagnostic efficacy of
florbetaben [10–13]. Validating the accuracy of ante-
mortem assessment of brain b-amyloid load requires corre-
spondence between PETand histology-determined presence
of b-amyloid deposits. Such validation has not been
achieved to date because of technical challenges in ensuring
the assessment of identical regions by PET readers and pa-
thologists (for further details, see Supplemental Material).
A pivotal histopathology phase 3 study is reported here inwhich the in vivo binding of florbetaben to b-amyloid was
assessed by comparing whole-brain visual reads and quanti-
tative analysis with the final neuropathological diagnoses of
b-amyloid in the brain. In a subgroup, the visual assessment
of slices with tissue-matched regions of interest (ROIs) on
the PET scans was compared with the exact tissue-
matched post-mortem brain tissue.2. Methods
2.1. Study population
An international open-label, nonrandomized, multicenter
phase 3 study (ClinicalTrials.gov: NCT01020838) was con-
ducted in accordance with the Declaration of Helsinki. Ap-
provals by regulatory authorities and ethics committees
were obtained. Participants were recruited at 15 centers
(including dementia clinics with brain bank experience, hos-
pices, private practices, and dementia self-help groups) in
Australia, Europe, Asia, and North America, and examined
between February 2010 and July 2013. Patients with AD, de-
mentia with Lewy bodies (DLB), or other dementias, and
nondemented individuals, were included. Key exclusion
criteria included severe cerebral large-vessel disease, brain
tumors, and severe cardiovascular instability requiring inten-
sive care surveillance or therapeutic intervention.
Participants (or their legal representatives) provided writ-
ten informed consent to undergo brain magnetic resonance
imaging (MRI), a PET scan with florbetaben, and to donate
their brain for post-mortem examination. Participants
received compensation for expenses incurred (e.g., travel),
but no financial reward.
A cohort of young, cognitively normal healthy volunteers
(age, 22–38 years), considered highly likely to be b-amyloid
negative, was also recruited and studied by PET and MRI.
Volunteers provided written informed consent before study
procedures were carried out.
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PET imageswere acquired fromparticipants 90 to 110mi-
nutes after intravenous injection of 300 MBq6 20% florbe-
taben [14] according to a standardized acquisition and
image-processing protocol established during a technical
visit to each center. Three-dimensional volumetric T1-
weighted brain MRI data (e.g., magnetization prepared rapid
gradient echo or spoiled gradient recalled sequences) were
also collected.
2.3. Post-mortem brain histopathology
Brain samples from participants who died during the
study were used to determine the histopathology standard
of truth.
For whole-brain analysis, amyloid histopathology was
assessed according to the Consortium for Establishing a
Registry for Alzheimer Disease (CERAD) scores [15].
Tissue was regarded as positive when sufficient neuritic
plaques, detected by Bielschowsky silver staining, were
present to meet criteria for AD (CERAD score of
“frequent” or “moderate”). Histopathology was regarded
as negative when the CERAD score was “absent” or
“sparse.” Diffuse plaques do not contribute to the CERAD
score. The onsite pathologist conducted the autopsy (within
36 hours of death) and performed the CERAD scoring. In
the first 31 brains examined, six brain regions were addi-
tionally dissected (middle frontal gyrus, occipital cortex,
hippocampus/parahippocampal gyrus, anterior cingulate
cortex, posterior cingulate cortex/precuneus, and cerebellar
cortex). These regions were considered accessible for exact
removal and suitable for coregistration and direct correla-
tion of b-amyloid load as detected by in vivo PET imaging
and post-mortem histopathology. Brain removal, cutting,
block removal, photography, and embedding were per-
formed according to a predefined standardized procedure
(see Supplemental Material) to allow for alignment with
the MRI and PET image data. Samples were processed
for modified Bielschowsky silver staining [16] and immu-
nohistochemistry (IHC) for a beta with the monoclonal
6E10 antibody (Zytomed Systems, Berlin, Germany) (see
Supplemental Material) in a core laboratory. The same
tissue-section was then identified in MRI and PET images.
A section of up to 3.0! 2.5 cm was used for each area for
the histopathology assessment by a neuropathology
consensus panel (three neuropathology experts) to semi-
quantitatively determine the density of neuritic and diffuse
plaques separately as absent, sparse, moderate, or frequent
according to Mirra et al. [15].
For tissue-matched ROI analyses, an ROI was considered
positive if there were moderate neuritic/cored or diffuse
plaques, according to Bielschowsky silver staining or IHC.
Diffuse plaques were identified based on the morphological
appearance on either Bielschowsky silver staining or IHC
and scored in the same way as neuritic plaques (see
Supplemental Material).2.4. PET image processing
Full description of MRI and PET image processing is
provided in the Supplemental Material. Briefly, T1-
weighted volumetric MRI for each participant was aligned
with the photodocumented gross brain obtained at autopsy
along the sagittal plane for coregistration. As the macro-
scopic pathology slices were cut at 1-cm intervals, the
MRI was also “sliced” at 1-cm intervals. The accuracy
of MRI slicing was compared against the photodocu-
mented coronal pathology slices and, after several itera-
tions, made to align precisely. Next, an ROI was drawn
on the coronal MRI slices corresponding to the exact tis-
sue region removed post-mortem for histopathological
analysis. This was achieved by comparing the MRI with
the photodocumented coronal slices showing where the
tissue block had been extracted. Finally, the PET image
was spatially normalized to the realigned MRI, and
1-cm-thick coronal PET images corresponding to the
resliced MRI were obtained.
2.5. PET image data assessment
The comparison of whole-brain pathology with whole-
brain imaging was made using a visual assessment method
proposed for routine clinical use, developed to be indepen-
dent of the availability of MRI scans. In a subgroup of par-
ticipants, comparisons were made between regional brain
pathology and tissue-matched ROIs placed on the PET scans
(for more information, see Supplemental Material).
PET images were assessed by three in-person trained, in-
dependent readers who were blinded to the clinical and his-
topathology results. Whole-brain visual assessment used
methodology adapted from previously described techniques
[10,12]. This involved a regional cortical tracer uptake
scoring system (1 5 no tracer uptake, 2 5 moderate tracer
uptake, 3 5 pronounced tracer uptake) in four brain areas,
with the resulting scores condensed into a binary
interpretation (score 1 5 negative; score 2 or
3 5 positive). In both whole-brain and tissue-matched ROI
analyses, visual assessments were compared with histopa-
thology results, and a majority-read approach was used to
calculate diagnostic efficacy.
For the whole-brain quantitative analysis, composite
cortical standardized uptake value ratios (SUVRs) were
determined as previously described [12], and receiver oper-
ating characteristic (ROC) curve analysis was used to ascer-
tain the optimal threshold for the sensitivity/specificity
calculation. The SUVR that provided the highest sum of
sensitivity and specificity as cutoff was determined.
2.6. Statistical analyses
Two-sided 95% confidence intervals (CIs) were calcu-
lated [17]. Sensitivity and specificity (see Supplemental
Material) were evaluated using normal approximation with
95%CIs. Normal approximation/exact binomial distribution
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ificity of the whole-brain blinded read.
Inter- and intrareader agreements were estimated through
kappa coefficients [18]. Differences between demographic
parameters and SUVRs were tested using the independent
two-sample t-test for continuous variables, or Fisher exact
test for dichotomous variables. Correlations were calculated
using Spearman correlation coefficients with 95% CIs. Ana-
lyses of variance (ANOVAs) together with the Tukeymultiple
comparison test were used to investigate the association be-
tween the composite SUVRs and the CERAD scores. Unless
stated, all data are given as mean value6 standard deviation.3. Results
3.1. Study population
Of 253 individuals screened, 218 (86%) were enrolled
(Fig. 1), including 139 with a clinical diagnosis of AD, 5
with a clinical diagnosis of DLB, 31 with other dementias,
32 without dementia (primarily with oncological disorders),
and 11 young, cognitively normal volunteers.
In total, 216 participants underwent florbetaben injection
and PET imaging, including 205 end-of-life individuals
(52% male; mean age, 76.9 6 11 [range, 48–98] years)
and 11 healthy volunteers. As of July 2013, 74 participants
had died (mean age 80.46 10.4 years; Table S1) and under-
gone autopsy and post-mortem histopathology. The cohort
included 57 patients with a clinical diagnosis of AD, 3
with DLB, 6 with other dementias, and 8 without dementia.
The mean time from scan to death was 329 6 272 days
(Table S1); 46 (62%) participants died within 1 year of the
PET image being obtained, 20 (27%) within 2 years, and 8
(11%) after this time point. All 74 brains were used in the
whole-brain analysis, and data from the first 31 participants
who died formed the tissue-matched ROI-analysis subgroup.
In addition, florbetaben PET data were analyzed from 10
young cognitively normal volunteers (the remaining volun-
teer was excluded because of a major protocol deviation).
3.2. Whole-brain analysis: Histopathology
The presence of neuritic b-amyloid plaques was
confirmed in 47 of the 74 participants using histopathology,
including only 44 of the 57 patients with a clinical diagnosis
of AD, 1 of the 3 patients with DLB, 1 of the 6 individuals
with “other” dementias, and 1 of the 8 individuals without
dementia. Of the 13 patients with a clinical diagnosis of
AD but no neuritic plaques, 12 had other neurodegenerative
pathologies and 1 had no pathologically relevant changes.
Overall, neuritic plaques were absent (i.e., “absent” or
“sparse” neuritic plaque CERAD score) in 27 participants,
including four with no neurodegenerative pathologies, and
23 with neurodegenerative pathologies other than AD
(e.g., Parkinson’s disease, Pick’s disease and other forms
of frontotemporal lobar degeneration, multisystem glial,
and neuronal tauopathy).3.3. Whole-brain analysis: Florbetaben PET
Scans were read as positive in 46 of the 47 cases with
positive Bielschowsky silver staining (i.e., with moderate
or frequent neuritic plaques on histopathology), and as
negative in 24 of the 27 cases with sparse or absent neuritic
plaques on histopathology. This resulted in a sensitivity of
97.9% (95% CI 93.8–100%) and a specificity of 88.9%
(95% CI 77.0–100%) for florbetaben PET in detecting/
excluding neuritic plaques (k 5 0.90 [95% CI 0.81–
0.98]) (Table 1). The negative and positive predictive
values for florbetaben PET were 96.0% (95% CI 88.3–
100%) and 93.9% (95% CI 87.2–100%), respectively. A
paradigmatic case with the brain regions to be assessed in
the whole-brain analysis is shown in Fig. S1. All four pa-
tients without neurodegenerative pathologies, and 20 of
the 23 patients with non-AD neurodegenerative pathol-
ogies, were read as florbetaben PET negative.
The whole-brain quantitative florbetaben PETassessment
included 73 scans; one was excluded because the MRI scan
was of insufficient quality for gray versus white matter seg-
mentation. Composite gray matter SUVRs were signifi-
cantly higher in patients with b-amyloid plaques versus
those without (1.716 0.27 vs 1.246 0.18; Fig. 2). ANOVA
correlation analysis between CERAD scores and composite
SUVRs found a highly significant (P , .00001) positive as-
sociation. Tukey multiple comparison test showed signifi-
cant differences in composite SUVRs between CERAD
groups as follows: composite SUVRsCERAD C . composite
SUVRsCERAD 0 (P , .00001), composite SUVRsCERAD
C . composite SUVRsCERAD A (P 5 .0004), composite
SUVRsCERAD B . composite SUVRsCERAD 0 (P 5 .033),
and composite SUVRsCERAD C . composite SUVRsCERAD
B (P 5 .035). ROC curve analysis of composite gray matter
SUVRs resulted in a cutoff that allowed the whole-brain
analysis group to be best separated into florbetaben-
positive or florbetaben-negative brains. This was achieved
with an SUVR of 1.478, resulting in a sensitivity of 89.4%
(95% CI, 80.6–98.2%) and a specificity of 92.3% (95% CI,
82.1–100%) to detect b-amyloid plaques via florbetaben
PET data quantification (Fig. 2).
3.4. Tissue-matched ROI analysis
Six ROIs matching the size and location of the six tissue
blocks assessed by pathologists were placed on each of the
scans from the first 31 patients who died. Similar ROIs
were placed on scans from the 10 healthy volunteers (consid-
ered to be amyloid negative) (Fig. 1). In total, 244 tissue-
matched ROIs were assessed, of which 106 were positive
for plaques on histopathology.
A high level of interreader agreement was achieved for all
brain ROIs (k 5 0.66) (Table S2). Eighty-two of 106 ROIs
were read as true PET positive, and 130 of 138 ROIs as
true PET negative (Table 2; Fig. 3). In areas known to
show b-amyloid plaques more frequently in AD (i.e., frontal
cortex, anterior cingulate, posterior cingulate/precuneus
Fig. 1. Study flowchart of different trial stages. Two participants were enrolled but were not administered the positron emission tomography (PET) tracer as a
result of death or adverse event after study inclusion. Ten healthy volunteers whowere imagedwith florbetaben in this trial were included by considering them as
amyloid negative by definition. Tissue-matched region of interest (ROI) analysis was performed on a brain region-level basis considering central histopathology
assessment by Bielschowsky silver staining and b-amyloid immunohistochemistry (IHC) as standard of truth with the first 31 available post-mortem cases.
Whole-brain analysis was performed and compared against onsite histopathology assessment with the Consortium for Establishing a Registry for Alzheimer
Disease (CERAD) system as standard of truth in all 74 available post-mortem cases.
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specificity was 86–95%. Sensitivity was lower (57%) but
specificity higher (100%) for the hippocampus, resulting in
an overall sensitivity of 77.4% (95% CI 65.3–89.4%) and
a specificity of 94.2% (95% CI 88.6–99.8%) for all ROIs.
In the tissue-matched ROI quantitative florbetaben PET
assessment, significantly higher SUVRs were found for re-
gions confirmed to have the histopathological evidence ofb-amyloid compared with regions that were scored negative
for b-amyloid, with the exception of the hippocampus/para-
hippocampal gyrus, consistent with the visual assessment
(Table 2; Fig. S2).
Regional florbetaben SUVRs correlated significantly
with the consensus panel histopathology scores for neuritic
and diffuse plaques in the middle frontal gyrus (r 5 0.62
[95% CI 0.49–0.72]), occipital cortex (r 5 0.48 [95% CI
Table 1
Visual assessment of florbetaben PET images by three blinded readers in the
whole-brain analysis group (n 5 74)
Estimate 95% Lower CI 95% Upper CI
Sensitivity (%)
Majority read 97.9 93.8 100.0
Reader 1 97.9 93.8 100.0
Reader 2 100.0 92.5 100.0
Reader 3 97.9 93.8 100.0
Specificity (%)
Majority read 88.9 77.0 100.0
Reader 1 88.9 77.0 100.0
Reader 2 85.2 71.8 98.6
Reader 3 85.2 71.8 98.6
Abbreviations: PET, positron emission tomography; CERAD, Con-
sortium for Establishing a Registry for Alzheimer Disease; SUVRs, stan-
dardized uptake value ratios; CI, confidence interval.
NOTE. Onsite histopathology assessment by the CERAD criteria served
as standard of truth.
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0.60–0.78]), and the posterior cingulate cortex/precuneus
(r5 0.62 [95% CI 0.50–0.72]), but not in hippocampus/par-
ahippocampal gyrus (r 5 0.18 [95% CI 0.01–0.35]). The
respective box plots are provided in Fig. S3.
To determine the relationship between histopathological-
ly determined plaque type and florbetaben uptake, neocor-
tical gray matter ROIs with b-amyloid histopathology
were considered: 21 with predominantly diffuse plaques,
and 60 with both diffuse and neuritic plaques. In every
instance, regions with neuritic plaques also had diffuse pla-
que deposition. No significant florbetaben SUVR differences
were found between the two different plaque types, whereas
both groups had significantly higher SUVRs compared with
the plaque-negative ROIs (Fig. 2).4. Discussion
Results from this study of florbetaben PET imaging to
detect b-amyloid deposits in the brains of individuals with
dementia demonstrate that the method used for the visual
assessment was reliable and suitable for use in clinical prac-
tice. Indeed, florbetaben has been approved in the EU and
USA in conjunction with a clinical evaluation, for PET im-
aging of b-amyloid neuritic plaque density in the brains of
adult patients who are being evaluated for AD and other
causes of cognitive impairment.
In the whole-brain analysis of 74 brains, the high sensi-
tivity and specificity associated with the visual analysis
(97.9% and 88.9%, respectively) were consistent with the
sensitivity and specificity obtained using quantitative assess-
ment of the PET images (89.4% and 92.3%, respectively).
The sensitivity of the whole-brain analysis was, however,
substantially higher than that of the tissue-matched ROI
analysis. This is due in part to the lack of sensitivity in the
hippocampus/parahippocampal gyrus. This region contains
gray and white matter within a relatively small volume andis often atrophic, making it prone to partial volume effects.
These characteristics made it difficult for the blinded imag-
ing readers to properly assess this specific region. SUVR
analysis for this region corroborated this difficulty in assess-
ment. Importantly, florbetaben PET imaging had a high
negative predictive value (96.0%), indicating that a PET
scan evaluated as negative is a reliable indicator of the
absence of sufficient plaque pathology in the brain to support
a diagnosis of AD. In addition, the high positive predictive
value confirms that florbetaben PET provides a reliable
detection of plaques. It is important to note that the presence
of b-amyloid plaques alone is not sufficient to diagnose AD,
although cognitive impairment in the presence of b-amyloid
plaques is strongly suggestive of AD. Consistent with previ-
ous studies, only 44 of 57 (77%) patients with a clinical diag-
nosis of AD in the present study were actually found to have
brain b-amyloid [21].
The tissue-matched ROI validation of this study is the
first direct, region-by-region anatomical comparison of an
18F-labeled b-amyloid-targeted PET tracer uptake with
post-mortem histopathologically determined b-amyloid
load in matched tissue sections and imaging ROIs. In previ-
ous studies, in vivo versus post-mortem b-amyloid signal as-
sociation was established solely using whole-brain PET
assessment [22,23], which precluded detailed direct
anatomic association between tracer uptake and b-amyloid
plaques. Furthermore, PET data in previous studies were
analyzed without corresponding the assessment of
individual brain structural information provided by MRI.
Our technique for region matching in vivo PET data with
post-mortem histopathology data assured that identical brain
regions were evaluated by both PET and histopathology
readers, and that the gray matter was precisely separated
within the ROIs from the white matter, where b-amyloid
tracers are assumed to bind nonspecifically [24]. Hence,
this study method provides an exact tissue-matched compar-
ison of in vivo ROIs with post-mortem sections for vali-
dating the accuracy of florbetaben binding to b-amyloid.
Another advantage of this direct regional assessment of
PETand histopathology was to allow the analysis of the abil-
ity of florbetaben to bind to diffuse and neuritic plaques.
Although there is growing evidence that all b-amyloid
deposits add to the course of AD [25], and the National Insti-
tute on Aging - Alzheimer’s Association NIA-AA guidelines
added nonneuritic b-amyloid deposition in form of modified
Thal stages to the neuropathological assessment of AD [26],
the binding of b-amyloid imaging agents to diffuse plaques
is controversial and not well studied [27,28]. Here, we
provide the largest set of brain sections with an
appropriate methodology to confirm that florbetaben binds
to both neuritic and diffuse plaques in vivo.
One limitation of the study, which is also applicable to
other comparisons of in vivo b-amyloid PET imaging with
post-mortem histopathology [22,23], is that clinical
features of end-of-life individuals had significant end-stage
medical illnesses that could bias the PET data. For example,
Fig. 2. Florbetaben uptake quantification in relation to brain plaque load and plaque types. (A) Boxplots of the composite standardized gray matter uptake value
ratios (SUVRs) of florbetaben positron emission tomography (PET) imaging in whole-brain analysis group subjects with and without b-amyloid plaques. Mean
SUVRs were compared against presence/absence of neuritic plaques as determined by onsite post-mortem histopathology according to Consortium for Estab-
lishing a Registry for Alzheimer Disease (CERAD) criteria. The boxes showmedian values and first (Q1) and third (Q3) quartiles. Thewhiskers represent Q16
1.5 of the interquartile ranges. (B) Receiver operating characteristic (ROC) curve for the composite gray matter SUVRs of florbetaben PET imaging in discrim-
inating between whole-brain analysis group subjects with and without b-amyloid plaques. The area under the ROC curve was 0.914. According to this ROC
statistics, the optimal separation SUVR threshold was determined as 1.48. Application of this cutoff SUVR resulted in a sensitivity and specificity of 89.4% and
92.3% of florbetaben PET in detecting b-amyloid plaques. (C) The influence of the b-amyloid plaque type as detected by centralized post-mortem histopathol-
ogy using Bielschowsky silver staining and b-amyloid immunohistochemistry (IHC) in the tissue-matched graymatter region of interest (ROI) analysis group on
the in vivo florbetaben uptake. Sixty ROIs exhibiting both diffuse and neuritic b-amyloid plaques were compared with 21 gray matter ROIs exhibiting predom-
inantly diffuse b-amyloid plaques and 41 gray matter ROIs without b-amyloid plaques. Ab, b-amyloid. (D) Florbetaben PET-positive case with predominantly
diffuse plaque pathology. Coronal T1 magnetization prepared rapid gradient echo magnetic resonance (MR) slice (upper left) at the level of the posterior cingu-
late cortex/precuneus region of interest in which gray matter was segmented for gray matter PET analysis (blue box), corresponding coronal florbetaben
PET slice (upper right) with posterior cingulate cortex/precuneus volume of interest (blue box) which was rated by the blinded readers as positive for cortical
b-amyloid, corresponding post-mortem histopathology image of Bielschowsky silver staining (lower left) and IHC using monoclonal antibody 6E10 (lower
right) predominantly exhibiting diffuse gray matter plaques. Black scale bars in histopathology images represent 200 mm.
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Table 2
Region-level visual and quantitative assessment of post-mortem tissue-matched florbetaben PET images (tissue-matched ROI analysis of 244 brain regions)
ROI (tissue matched)
Potential
b-amyloid load
Tissue-matched ROI visual assessment (majority read) Tissue-matched ROI quantitative assessment (SUVR)
b-Amyloid in histopathology
[TP/(TP 1 FN) (sensitivity
[95% CI])]
No b-amyloid in
histopathology [TN/(TN 1 FP)
(specificity [95% CI])]
b-Amyloid in histopathology
[mean6 SD (sensitivity [95% CI])*]
No b-amyloid in histopathology
(mean 6 SD (specificity [95%
CI])y]
SUVR difference
(95% CI)
Middle frontal gyrus Intense [19] 18/21 (85.7% [70.7–100%]) 19/20 (95.0% [85.4–100%]) 1.30 6 0.30** (90% [77.2–100%]) 0.95 6 0.12 (80% [62.5–97.5%]) 0.35 (0.20–0.51)
Occipital cortex Low [19] 16/18 (88.9% [74.4–100%]) 19/22 (86.4% [72.0–100%]) 1.34 6 0.27** (89% [74.5–100%]) 1.10 6 0.10 (67% [47.3–86.4%]) 0.23 (0.09–0.38)
Hippocampus/
parahippocampal
gyrus
Low; significant
atrophy [19,20]
12/21 (57.1% [36.0–78.3%]) 20/20 (100% [83.1–100%]) 0.99 6 0.21 (71% [51.6–90.4%]) 0.92 6 0.17 (60% [38.5–81.4%]) 0.07 (20.08–0.22)
Anterior cingulate
cortex
Intense [19] 18/20 (90.0% [77.0–100%]) 18/21 (85.7% [70.7–100%]) 1.36 6 0.26*** (80% [62.4–97.5%]) 0.96 6 0.15 (100% [83.9–100%]) 0.39 (0.24–0.54)
Posterior cingulate
cortex/precuneus
Intense [19] 18/22 (81.8% [65.7–98.0%]) 17/18 (94.4% [83.9–100%]) 1.49 6 0.35** (82% [66.0–98.0%]) 1.06 6 0.09 (100% [81.5–100%]) 0.43 (0.26–0.59)
Cerebellar cortex Reference [19] 0/4 (0.0% [0.0–60.2%]) 37/37 (100% [90.5–100%]) z z
All 82/106 (77.4% [65.3–89.4%]) 130/138 (94.2% [88.6–99.8%])
Abbreviations: PET, positron emission tomography; ROI, region of interest; FN, false negative; FP, false positive; CERAD, Consortium for Establishing a Registry for Alzheimer Disease; SUVR, standardized
gray matter uptake value ratio using the cerebellar cortex as reference region; TN, true negative; TP, true positive; CI, confidence interval.
NOTE. Centralized histopathology assessment using Bielschowsky silver staining and b-amyloid IHC served as the standard of truth. Column 2 describes knowledge from literature on the usual amount of
b-amyloid load in case of AD in the ROIs deliberately selected in this study to obtain a wide spectrum with different degrees of expected b-amyloid pathology. Group differences were tested for significance using
the t-test for independent samples.
*P , .05; **P , .01; ***P , .001 vs “no b-amyloid histopathology.”
yDerived from receiver operating characteristic curve analyses.
zReference region for SUVR calculation.
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Fig. 3. Two paradigmatic tissue-matched region of interest (ROI) analysis examples. The upper row shows results from a b-amyloid-positive patient
(Case 48) and the lower row shows findings from a b-amyloid-negative patient (Case 45). Coronal T1 magnetization prepared rapid gradient echo mag-
netic resonance (MR) slices at the level of the posterior cingulate cortex/precuneus ROI (A, E), corresponding coronal florbetaben positron emission
tomography (PET) slices (B, F), corresponding post-mortem coronal brain slice photodocumentation (C, G), and corresponding histopathology images
(black scale bars representing 200 mm) of Bielschowsky silver staining (D, H). Based on the photodocumented size and position of the posterior cingulate
cortex/precuneus brain blocks, which were removed post-mortem, respective ROIs were defined on the individual in vivo MRI and coregistered florbe-
taben PET imaging data (blue boxes). Note that PET/MRI versus brain slice coregistration was optimized toward the ROI, as it was not possible to
perfectly fit all brain parts in the respective slices due to post-mortem brain shrinkage and deformation. Within the ROIs, the gray matter was segmented
for tracer uptake analysis. In concordance with the results of the Bielschowsky silver staining that revealed plaque positivity (D) and negativity (H),
cortical florbetaben uptake was evident (B), and absent (F).
O. Sabri et al. / Alzheimer’s & Dementia- (2015) 1-11 9some patients had pronounced brain atrophy, which made vi-
sual assessment of the PET scans challenging, negatively
biasing the association between the PET and histopathology
signals. Furthermore, the possibility cannot be excluded that
the pharmacodynamics and pharmacokinetics of b-amyloid-
targeted PET tracers are different in end-of-life patients
compared with earlier stage patients in whom PET has
greater clinical relevance and in whom future clinical appli-
cation is desired. If b-amyloid PET imaging is to be used
routinely in the clinical assessment of such patients, then
there is a need for large-scale controlled diagnostic trials
in patients in the early stages of dementia [12]. Only such
studies, together with pivotal in vivo PET versus post-
mortem histopathology comparisons as carried out in the
present study, will provide the full picture of the clinical ef-
ficacy of b-amyloid PET imaging as an adjunct to clinical
assessment for early, ante-mortem diagnosis of AD and pro-
dromal AD.
In conclusion, high sensitivity and specificity, and high
predictive values for florbetaben PET, were confirmed by
histopathology in clinically relevant whole-brain visual ana-
lyses, allowing the reliable detection and exclusion of amy-
loid pathology. Moreover, this study involved the rigorous
validation of florbetaben PET in an exact tissue-matched
ROI analysis. These data, together with the results from
earlier studies [10–12,14,29–31], support the value of
florbetaben PET as a diagnostic marker, particularly as avaluable adjunct for the exclusion of AD or differential
diagnosis of dementia.
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1. Systematic review: Only one clinical trial with two
publications [22,23] is reported in PubMed
comparing an 18F-labeled b-amyloid agent against
autopsy-derived histopathology.
2. Interpretation: In our study, which is the second to be
reported meeting the aforementioned criteria, florbe-
taben positron emission tomography (PET) was
investigated in a global phase 3 trial. A high diag-
nostic efficacy was determined for the detection of
neuritic plaques in 74 deceased subjects. In a sub-
group, an exact tissue-scan matched analysis was
performed in 244 samples. As such, it is the first trial
to directly compare PET regions ante-mortem to
identical tissue regions analyzed post-mortem.
Florbetaben PET confirmed efficacy for the in vivo
detection of b-amyloid deposits, both on a whole
brain and on a regional brain level.
3. Future directions: Trials testing b-amyloid PET in
the early dementia stage are needed and the influence
of plaque morphology on the PET signal needs to be
further explored.References
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